Charles River Laboratories International, Inc. (NYSE:CRL) Given Average Rating of "Hold" by Brokerages

Key Points

• Charles River Laboratories International, Inc. has received an average recommendation of "Hold" from 15 research firms, with one sell, nine hold, and five buy ratings.
• The company's average 12-month price target among brokerages is $175.69, indicating some optimism for share performance despite current sentiments.
• Charles River Laboratories reported $3.12 earnings per share for the last quarter, surpassing analysts' expectations of $2.50, with revenue up 0.6% year-over-year.

Charles River Laboratories International, Inc. (NYSE:CRL - Get Free Report) has received an average rating of "Hold" from the fifteen brokerages that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, nine have assigned a hold recommendation and five have issued a buy recommendation on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $175.6923.

A number of research analysts recently commented on CRL shares. Wall Street Zen downgraded Charles River Laboratories International from a "strong-buy" rating to a "buy" rating in a report on Sunday, August 17th. JPMorgan Chase & Co. increased their price target on Charles River Laboratories International from $145.00 to $160.00 and gave the company a "neutral" rating in a report on Thursday, August 7th. TD Cowen raised Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 price target for the company in a report on Wednesday, May 14th. Robert W. Baird upped their price objective on Charles River Laboratories International from $118.00 to $140.00 and gave the company a "neutral" rating in a research note on Thursday, May 8th. Finally, Cowen upgraded Charles River Laboratories International from a "hold" rating to a "buy" rating in a research note on Wednesday, May 14th.

Charles River Laboratories International Stock Up 0.0%

CRL traded up $0.07 on Tuesday, reaching $163.29. The company's stock had a trading volume of 860,239 shares, compared to its average volume of 956,203. The stock has a market cap of $8.04 billion, a price-to-earnings ratio of -122.77, a price-to-earnings-growth ratio of 5.22 and a beta of 1.47. Charles River Laboratories International has a 1 year low of $91.86 and a 1 year high of $230.02. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.36 and a quick ratio of 1.10. The business's 50 day moving average is $159.32 and its 200 day moving average is $148.75.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The medical research company reported $3.12 EPS for the quarter, beating analysts' consensus estimates of $2.50 by $0.62. The firm had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $983.76 million. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.Charles River Laboratories International's revenue for the quarter was up .6% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.80 earnings per share. As a group, research analysts forecast that Charles River Laboratories International will post 9.36 EPS for the current fiscal year.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 800 shares of the company's stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $157.60, for a total transaction of $126,080.00. Following the sale, the executive vice president owned 24,116 shares in the company, valued at $3,800,681.60. This represents a 3.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 1.30% of the stock is owned by insiders.

Institutional Trading of Charles River Laboratories International

Institutional investors and hedge funds have recently bought and sold shares of the company. Rothschild Investment LLC raised its stake in Charles River Laboratories International by 480.0% during the first quarter. Rothschild Investment LLC now owns 174 shares of the medical research company's stock valued at $26,000 after buying an additional 144 shares in the last quarter. Brooklyn Investment Group raised its position in shares of Charles River Laboratories International by 93.5% during the 1st quarter. Brooklyn Investment Group now owns 178 shares of the medical research company's stock worth $27,000 after purchasing an additional 86 shares during the period. Cromwell Holdings LLC raised its position in shares of Charles River Laboratories International by 542.9% during the 2nd quarter. Cromwell Holdings LLC now owns 180 shares of the medical research company's stock worth $27,000 after purchasing an additional 152 shares during the period. Neo Ivy Capital Management acquired a new stake in shares of Charles River Laboratories International during the 2nd quarter worth approximately $29,000. Finally, HM Payson & Co. acquired a new stake in shares of Charles River Laboratories International during the 1st quarter worth approximately $31,000. Institutional investors and hedge funds own 98.91% of the company's stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).